Our findings on a key role of cIAPs for the antitumor effects of CD137 agonists have important translational implications in cancer immunotherapy based on CAR T cells and CD137 agonists that are being developed in the clinic in different combinations (64, 72). Here, TNFRSF9 is linked to cancer.